FDA 483 - Apitoria Pharma Private Limited - May 19, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Aurobindo Pharma Limited, Unit XIV, an API manufacturer in Anakapalli District, India, revealed significant deficiencies. Observations included inadequate manufacturing equipment cleaning and storage, improper resealing of API product drums, and raw materials stored outside specified conditions. Additionally, laboratory controls were found lacking, with issues in instrument verification, secondary standard qualification, and chromatographic test precision.
ID · 38af609e-8879-4c0f-80c9-c894629e447d